Medical and Pharmaceutical Lipella Pharmaceuticals skyrockets on FDA access approval for mouth disease treatment The stock was up by about 200% during early trading hours Rowan DunneFebruary 6, 2025
Medical and Pharmaceutical BioAge Labs craters after dropping clinical study on top drug candidate for obesity Usage of the therapeutic resulted in unhealthy levels of transaminases (liver enzymes) in participants Rowan DunneDecember 9, 2024
Medical and Pharmaceutical Kentucky governor recognizes Lung Cancer Awareness Month with formal proclamation Kentucky has the highest rate of the disease in the country, largely attributable to a vast number of smokers Rowan DunneNovember 26, 2024
Medical and Pharmaceutical Neurogene patient dies in drug trial, stock surges after FDA says ‘use lower dose’ This unfortunate incident occurred during a study on the company's Rett syndrome therapeutic NGN-401 Rowan DunneNovember 22, 2024
AI and Autonomy Qure.ai’s qXR software helps provide Scottish woman with lung cancer diagnosis A timely follow up low-dose CT scan confirmed that she had the disease Rowan DunneNovember 14, 2024
Medical and Pharmaceutical Chinese researchers develop breath analysis tech for lung cancer detection It works by identifying abnormal levels of isoprene -- a volatile organic compound Rowan DunneNovember 6, 2024
Medical and Pharmaceutical Largest U.S. municipal healthcare system does over 10K lung cancer screenings since 2022 The achievement was announced as Lung Cancer Awareness Month begins Rowan DunneNovember 4, 2024
Medical and Pharmaceutical South Korea’s Yuhan has 690% profit spike on U.S. lung cancer drug sales Lazertinib, developed in partnership with Janssen Biotech, received FDA approval in August Rowan DunneOctober 28, 2024
Medical and Pharmaceutical New program aims to improve Florida’s lung cancer screening rate exponentially It is being implemented before Lung Cancer Awareness Month in November Rowan DunneOctober 24, 2024
Medical and Pharmaceutical Bright Minds Bio soars on US$35M private placement; up 5,400% in 5 days Developing drugs for the treatment of epilepsy, depression, obesity and other conditions is the company's forte Rowan DunneOctober 18, 2024